Alexza Pharmaceuticals and Grupo Ferrer have launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic patients in Austria, the companies said. Ferrer is working with Vienna-based AOP Orphan Pharmaceuticals to commercialize Adasuve in Austria.
Alexza President and CEO Thomas B. King commented, “With the launch of Adasuve in Austria, Ferrer continues to execute on its commercialization of the product. We are very pleased with Ferrer’s progress in making Adasuve available in an increasing number of countries throughout the EU. One of Alexza’s key priorities is to support the global roll-out of Adasuve, with manufacturing and other support activities, in collaboration with our commercial partners.”
Grupo Ferrer entered into an agreement with Alexza in 2011 to commercialize Adasuve in Europe, Commonwealth of Independent States countries, and Latin America.Ferrer launched Adasuve in Germany in July 2013 and said at the time that it expected to begin marketing the product in other European countries this year, continuing the European launch into 2014.
Read the Alexza press release.
